Safety and Efficacy of Daratumumab in Immune Thrombocytopenia.

已完结 20 由士多啤梨发布于 2025/10/29 15:04:31

DOI:10.1182/bloodadvances.2025017279
作者：Galina Tsykunova,?P?l Andre Holme,?Hoa Thi Thyuet Tran,?Henrik Frederiksen,?Eirik Tjonnfjord,?Ludvig A Munthe,?Elsa Drivet,?Hassen Kared,?Ingvild Hausberg S?rvoll,?Maria Therese Ahlen,?Matthieu Maheva
文献类型：期刊论文
补充材料：只需要正文

American Society of Hematology (ASH)

Abstract：Abstract: Resistance to B-cell-targeted therapies in immune thrombocytopenia (ITP) has been linked to persistence of autoantibody-producing CD38+ long-lived plasma cells. CD38 antibody darat

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierIsatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.